Company profile
MetaVia Inc. logo

MetaVia Inc.

Pipeline6 assets

  • DA-1726DA-1726 / GLP1R / GCGR (Glucagon-like peptide-1 receptor and glucagon receptor) / Oxyntomodulin (OXM) analogue / Cardiometabolic Diseases
    ObesityPhase 1ActiveGlobalMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1ActiveGlobal
  • VanoglipelDA-1241 / GPR119 (G-protein-coupled receptor 119) / Small Molecule / Cardiometabolic Diseases
    Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2aActiveGlobalType 2 Diabetes (T2D)Phase 1CompletedGlobal
  • ANA001ANA001 / Unknown / Oral Niclosamide Formulation / Infectious Diseases
    Moderate COVID-19Phase 2LegacyUS
  • NB-01NB-01 / Unknown / Unknown / Neurology
    Painful Diabetic NeuropathyUnknownLegacyGlobal
  • NB-02NB-02 / Unknown / Unknown / Neurology
    Cognitive Impairment / Neurodegenerative DiseasesUnknownLegacyGlobal
  • GemcabeneUnknown / Small Molecule / Cardiovascular / Infectious Diseases
    DyslipidemiaUnknownLegacyGlobalAcute COVID-19UnknownLegacyGlobal

Latest news15 items

All news

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE,

Presentation / Abstract • Phase 1Late-breaking poster presentation Wed, May 27, 2026, 8:30 AM CET

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

Three Late-Breaking Posters Highlight DA-1726, a GLP-1 /Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that

Presentation / Abstract • Phase 1Late-breaking poster presentation Sun, Jun 7, 2026, 12:30 PM ET

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step)

Presentation / Abstract • Phase 1EASL Congress 2026 poster presentation Thu, May 14, 2026

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

CAMBRIDGE, Mass. , Jan. 15, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock

MetaVia Inc. • Endpoint Arena